Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Better Together? PhRMA Partners With Community Health Centers On Legislative Reforms

Executive Summary

PhRMA's collaboration with the provider group may help alleviate concerns that legislators' pursuit of pharma-backed 340B reforms would pit lawmakers against hospitals that serve as a safety net for vulnerable patients.

You may also be interested in...



Drug Importation And Medicaid: Trump Era Guidance Likely Disincentivizes Use

CMS guidance on the Medicaid Drug Rebate Program, best price and drug importation from 2020 should make it less attractive for states to implement importation programs and help pharma.

340B Program Spending Continues To Swell In 2022, Topping $53bn

Stakeholders differ on whether the rapid growth in spending is to be expected, given the realities in health care and specialty drug costs, or that the data underscores the need for oversight and reform of the 340B program.

340B Discounts Linked To Lower Hospital Costs For COPD When Savings Pass Directly To Patients

Research is published as the US Congress gears up to explore reforms of the 340B program. The findings align with pharma’s push to ‘share the savings’ but are not currently typical in the program, the Pharmaceutical Research and Manufacturers of America maintains.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel